These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1813 related articles for article (PubMed ID: 12790696)

  • 41. A large, prospective, randomized, open-label, multicentre study of corticosteroid withdrawal in SPK transplantation: a 3-year report.
    Nakache R; Malaise J; Van Ophem D;
    Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii40-7, ii62. PubMed ID: 15814549
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tacrolimus as a rescue immunosuppressant after heart and lung transplantation. The U.S. Multicenter FK506 Study Group.
    Mentzer RM; Jahania MS; Lasley RD
    Transplantation; 1998 Jan; 65(1):109-13. PubMed ID: 9448154
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Initial experience with FK506 (tacrolimus) in pediatric renal transplant recipients.
    McKee M; Segev D; Wise B; Case B; Neu A; Fivush B; Colombani P
    J Pediatr Surg; 1997 May; 32(5):688-90. PubMed ID: 9165452
    [TBL] [Abstract][Full Text] [Related]  

  • 44. FK 506 therapy for refractory renal allograft rejection: lessons from liver transplantation.
    Woodle ES; Bruce DS; Josephson M; Newell KA; Piper JB; Millis JM; Cronin D; Whitman G; Ruebe M; Thistlethwaite JR
    Clin Transplant; 1996 Aug; 10(4):323-32. PubMed ID: 8884103
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group.
    Woodle ES; Thistlethwaite JR; Gordon JH; Laskow D; Deierhoi MH; Burdick J; Pirsch JD; Sollinger H; Vincenti F; Burrows L; Schwartz B; Danovitch GM; Wilkinson AH; Shaffer D; Simpson MA; Freeman RB; Rohrer RJ; Mendez R; Aswad S; Munn SR; Wiesner RH; Delmonico FL; Neylan J; Whelchel J
    Transplantation; 1996 Sep; 62(5):594-9. PubMed ID: 8830821
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients.
    Wiseman LR; Faulds D
    Drugs; 1999 Dec; 58(6):1029-42. PubMed ID: 10651389
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prevention of acute rejection with antithymocyte globulin (Thymoglobuline): its potential to reduce corticosteroids.
    Cantarovich D
    J Nephrol; 2004; 17 Suppl 8():S40-6. PubMed ID: 15599885
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The impact of age on rejection in kidney transplantation.
    de Fijter JW
    Drugs Aging; 2005; 22(5):433-49. PubMed ID: 15903355
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials.
    Knoll GA; Bell RC
    BMJ; 1999 Apr; 318(7191):1104-7. PubMed ID: 10213717
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral).
    Noble S; Markham A
    Drugs; 1995 Nov; 50(5):924-41. PubMed ID: 8586033
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients.
    Ettenger RB; Grimm EM
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 2):S22-8. PubMed ID: 11583941
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tacrolimus and steroids versus ciclosporin microemulsion, steroids, and azathioprine in children undergoing liver transplantation: randomised European multicentre trial.
    Kelly D; Jara P; Rodeck B; Lykavieris P; Burdelski M; Becker M; Gridelli B; Boillot O; Manzanares J; Reding R
    Lancet; 2004 Sep 18-24; 364(9439):1054-61. PubMed ID: 15380964
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunosuppression management in renal transplant recipients with normal-immunological risk: 10-year results from the Swiss Transplant Cohort Study.
    Krisl A; Stampf S; Hauri D; Binet I; Mueller T; Sidler D; Hadaya K; Golshayan D; Pascual M; Koller M; Dickenmann M; The Swiss Transplant Cohort Study Stcs
    Swiss Med Wkly; 2020 Nov; 150():w20354. PubMed ID: 33277913
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Performance of modified-release tacrolimus after conversion in liver transplant patients indicates potentially favorable outcomes in selected cohorts.
    Considine A; Tredger JM; Heneghan M; Agarwal K; Samyn M; Heaton ND; O'Grady JG; Aluvihare VR
    Liver Transpl; 2015 Jan; 21(1):29-37. PubMed ID: 25312292
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New-onset diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression.
    Wagner K; Webber SA; Kurland G; Boyle GJ; Miller SA; Cipriani L; Griffith BP; Fricker FJ
    J Heart Lung Transplant; 1997 Mar; 16(3):275-82. PubMed ID: 9087870
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Preoperative introduction and maintenance immunosuppression therapy of oral-only tacrolimus, mycophenolate mofetil and steroids reduce acute rejection episodes after lung transplantation.
    Bittner HB; Barten MJ; Binner C; Lehmann S; Garbade J; Hammerschmidt S; Wirtz H; Mohr FW
    Eur J Cardiothorac Surg; 2010 Sep; 38(3):268-76. PubMed ID: 20304665
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Randomized clinical trial of the effect of microemulsion cyclosporin and tacrolimus on renal allograft fibrosis.
    Murphy GJ; Waller JR; Sandford RS; Furness PN; Nicholson ML
    Br J Surg; 2003 Jun; 90(6):680-6. PubMed ID: 12808614
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A network meta-analysis of the efficacy of belatacept, cyclosporine and tacrolimus for immunosuppression therapy in adult renal transplant recipients.
    Goring SM; Levy AR; Ghement I; Kalsekar A; Eyawo O; L'Italien GJ; Kasiske B
    Curr Med Res Opin; 2014 Aug; 30(8):1473-87. PubMed ID: 24628478
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group.
    Lancet; 1994 Aug; 344(8920):423-8. PubMed ID: 7520105
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 91.